Psychedelics Therapy

Editor's Note: A prior version of this article was erroneously attributed to a different author. The article was written by Mattha Busby and originally published on DoubleBlind Mag. The article has been updated to reflect the appropriate byline and full content of the original...

Recent advancements in understanding mental health and the brain have allowed us to identify possible commonalities between different mental health conditions. One of the shared experiences among patients with conditions like treatment-resistant depression (TRD), bipolar II disorder and PTSD is the...

As of August 2, psychedelics and wellness company Silo Wellness (OTCQB: SILFF) and Jamaican NUGL Inc. (OTC Pink: NUGL) via the Kaya Group, are strategic partners offering a range of psychedelic wellness experiences and retreats in the Caribbean country. See Also: Jamaica...

Positive long-term follow-up data from Sunstone Therapies’ investigator-initiated Phase 2 study assessing COMPASS Pathways’ (NASDAQ: CMPS) synthetic psilocybin COMP360 paired with psychological support in cancer patients with Major Depressive Disorder (MDD) is out. 57% of patients...

Nora Volkow, the director of the National Institute on Drug Abuse (NIDA), said that psychedelic substances have promising potential for therapeutic uses, particularly for treating severe depression, post-traumatic stress disorder (PTSD) and addiction. Accelerating Research At a...

Specialty pharmaceutical company PharmaTher Holdings (OTCQB: PHRRF) has submitted a Fast Track Application to the Food and Drug Administration (FDA) for KETARX, a ketamine drug that may help treat levodopa-induced dyskinesia in Parkinson’s disease. Fast Track designation is for...

Grammy-winning musician and producer Wyclef Jean spoke to journalist Javier Hasse for Forbes about his cannabis use, its relationship to hip-hop culture and his involvement in the cannabis industry. Cannabis: A Journey to Creativity, Focus And Advocacy Jean started using...

Australia has announced that it will become the first country in the world to reschedule the medical use of MDMA and Psilocybin, two key ingredients in psychedelic drugs. On Feb. 3, the Therapeutic Goods Administration (TGA) revealed that these substances would be moved from Schedule 9, which...

The University of Exeter is launching a new postgraduate program on psychedelics, called "Psychedelics: Mind, Medicine, and Culture." The program aims to train therapists, mental health advocates, and healthcare workers on how to safely work with psilocybin, LSD, MDMA, and other...

Early-stage psychedelics manufacturing company Lucy Scientific Discovery Inc. (NASDAQ: LSDI) partnered with specialized firm Pramantha Group to obtain key government contracts and grants that would enhance its drug manufacturing capabilities to meet the growing demand. See Also: Lucy...

Private biopharma company People Science raised $5.3 million in its second seed round, which was led by Acre Venture Partners and followed by Bluestein Ventures, THIA Ventures and FORM Life Ventures. The company, which now has a total $8.5 million of seed funding, will use the latest capital to...

After a successful commercial production trial, life sciences biotech company Core One Labs Inc. (OTCQB: CLABF) is set to begin commercial production of its clinical-grade psilocybin at a Good Manufacturing Practices (GMP) facility in January 2023. In addition to psilocybin, the company intends to...

A new bill decriminalizing possession and personal use of certain psychedelics backed by mental health professionals and veterans and led by Sen. Scott Wiener (D-SF) was introduced in California’s Senate on Monday. This is Sen. Wiener’s second attempt in recent months to get ...

Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) shared its financial results and business highlights for a three-month period that ended Oct. 31, 2022. Financials showed: Revenue of $314.827 (CA$430,504) via Awakn's European clinics, compared to $Nil in the prior year. That's...

Psychedelic therapeutics biotech company PsyBio Therapeutics Corp. (OTCQB: PSYBF) has filed three additional U.S. provisional patent applications covering its latest discoveries on production of synthetic 5-MeO-DMT, AKA “toad venom” in that this psychedelic substance is naturally...